Value creation in life sciences – 16: Risk
In this video we discuss why we humans do not understand risk. The genes that our ancestors carried are passed down to us , hence our brain is wired to solve ancient problems and not modern ones.
Value creation in life sciences – 17
In this video, we discuss with Jose, who served as the CEO of Alex Therapeutics and have vast experience in Biotech, about portfolio management and risk taking in the Biotech space. The questions we discuss are : Given the returns…
Value creation in life sciences – 15: Scale
In this video, we discuss scale by providing analogy to why humans don’t grow like HULK. Then we discuss what all companies can do to scale well.
Value creation in life sciences – 14
In this video we discuss with Stephan Christgau, Founding partner Eir Ventures about mainly three questions : 1. Serendipity in Life Sciences : How much happenstance play a role and how does he choose the team that has an open-minded…
Value creation in life sciences – 13
In this video we chat with Edoardo Negroni to understand his perspective on Value creation, scaling up and responsibility towards patients. Edoardo is the Co-Founder and Managing partner of AurorA Science, a biotech investment company which invests with the aim…
Value creation in life sciences – 12: Scale
In this video, we discuss how the realised function of a system changes as we scale bigger. If you are a small company and suddenly become big, if not well planned, this could change its realised function and could lead…
Value creation in life sciences – 11: Scale
In this video we discuss the fundamentals of Scale, its meaning and try to find out how things scale as they grow. This gives us a food for thought to understand the non-linearity associated with growth in size.
Value creation in life sciences – 10: Right investors
In this video we discuss that VC investment is expensive and hence companies must also find out more about what types of Investors they are, how good are their networks, how decisions are made in partnerships – do the investor…
Value creation in life sciences – 9: VC vs Family office
In this video we discuss how to view these two investments if you are the CEO of a Biotech company. Both have certain pros and cons and depending on your stage of the company, capital needs, you could choose either…
Value creation in life sciences – 8
In this video we argue that taking a weighted average of different methods of valuation is not the correct way to do it. Every method is used in a different context. The worth of your asset, through Intrinsic value (NPV),…
